Andreessen Horowitz (a16z)

Leading technology venture capital firm with dedicated Bio+Health fund. Known for company-building platform approach and large-scale investments across software, crypto, and life sciences.

Location
Menlo Park, USA
Founded
2009
AUM
$35B+
Investment Range
$1M - $500M
Portfolio Companies
1
Focus
generalist
Fund Stages
seed, series-a, series-b, series-c, growth

Investment Thesis

Andreessen Horowitz Bio+Health invests in companies at the intersection of biology and technology, focusing on digital health, therapeutics, and healthcare infrastructure. They believe in the "software eating healthcare" thesis and back founders applying technology to transform healthcare delivery, drug discovery, and patient outcomes.

Team

Partners / Managing Directors (Health & Bio Focus)

  • Vijay Pande, PhD - General Partner, Bio+Health
  • Jorge Conde - General Partner, Bio+Health
  • Julie Yoo - General Partner, Bio+Health
  • Vineeta Agarwala, MD, PhD - General Partner, Bio+Health

Other Key Team Members

  • Marc Andreessen - Co-Founder & General Partner
  • Ben Horowitz - Co-Founder & General Partner

Focus Areas

  • Digital Health
  • Healthcare Technology
  • Therapeutics
  • Genomics
  • AI in Healthcare
  • Drug Discovery
  • Healthcare Infrastructure

Notable Exits

  • Lyra Health - Continued growth (valued at $5.6B)
  • Devoted Health - Continued growth
  • Freenome - Continued growth
  • Ultima Genomics - $600M funding round (2022)

Sources

Portfolio Companies

NameLocationFoundedCategories
Ultima GenomicsFremont, California, USA2016
genomics-sequencingbiotech+1